The Lancet Respiratory Medicine in conversation with – Détails, épisodes et analyse

Anne-Marie Dingemans, Isabelle Opiz, and Corinne Faivre-Finn talk about their multidisciplinary efforts to develop a consensus definition of stage III Non-Small Cell Lung Cancer technical resectability. 

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00051-2/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Anne Holland and Christine McDonald join Diana Stanley to discuss ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis.

Click here to read the full article, Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a randomised sham-controlled trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00005-6/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

This episode is in Italian. For the English version, please see the main feed.

Lorenzo Guglielmetti sul trial clinico ENDTB-Q per valutare l’efficacia e la sicurezza di un regime di farmaci per curare la tubercolosi in individui con tubercolosi pre-estesa farmaco-resistente.

Leggi l'articolo completo:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00194-8/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanres

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Deputy editor Ari Colosio speaks with Dr. Laura Garriga-Grimau of the Val d’Hebron Hospital, Autonomous University of Barcelona. Dr. Garriga-Grimau discusses the first multi-country cohort study to describe the clinical features and standards of care for children and young people with bronchiectasis, drawing on data from the International Pediatric Bronchiectasis Registry.

Together, they examine key findings on regional differences in diagnosis, co-morbidities, clinical severity, and treatment practices across eight countries. Dr. Garriga-Grimau highlights the significant burden of bronchiectasis on patients and health systems, as well as the urgent need for earlier diagnosis, harmonised international guidelines, and more equitable research and care.

Read the full article:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00089-X/abstract?dgcid=buzzsprout_icw_podcast_July_25_lanres

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Bianca Brandon is joined by Professor Marcus Schultz and Dr Prashant Nasa to discuss their recent Position Paper reporting insights from an international Delphi expert panel on defining and subphenotyping ARDS. The findings underscore the need to refine the ARDS definition to better address heterogeneity of the condition and improve diagnostic precision, with use of subphenotyping where appropriate.

Read the full article:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00115-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanres

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Bianca Brandon, Senior Editor at The Lancet Respiratory Medicine, is joined by Professor Hjalmar Bouma to discuss a new review on sepsis in immunocompromised patients, exploring the diagnostic challenges, complexities of immune status, and future directions for targeted therapies. The episode also analyses the increased vulnerability of specific patient groups, the importance of biomarker-driven personalised medicine, and the need for improved representation of immunosuppressed patients in clinical trials. 

Read the full article:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00124-9/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanres

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Deputy Editor of The Lancet Respiratory Medicine Ari Colosio discusses the critical findings of a new epidemiological study on pulmonary embolism in children and adolescents with Simon Wolf from the University Hospital of Zurich. 

This episode delves into the prevalence, risk factors, and clinical implications of this rare but serious condition, highlighting the need for increased awareness and further research.

Read the full article:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00412-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanres

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Sandeep Sahay and Professor Franck Rahaghi discuss their Personal View on future treatment paradigms in pulmonary arterial hypertension.

Read the full paper, Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, here: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00425-9/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv